Axsome Therapeutics (AXSM) Receives a Buy from Mizuho Securities

Mizuho Securities analyst Graig Suvannavejh maintained a Buy rating on Axsome Therapeutics (AXSMResearch Report) today and set a price target of $86.00. The company’s shares closed yesterday at $74.29.

According to TipRanks, Suvannavejh is a 4-star analyst with an average return of 5.3% and a 53.73% success rate. Suvannavejh covers the Healthcare sector, focusing on stocks such as Axsome Therapeutics, Bioxcel Therapeutics, and Karuna Therapeutics.

Axsome Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $109.30.

See the top stocks recommended by analysts >>

The company has a one-year high of $82.00 and a one-year low of $20.63. Currently, Axsome Therapeutics has an average volume of 1.27M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Axsome Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies for the management of central nervous system disorders. Its product candidates include AXS-02 and AXS-06 which are developing for multiple indications. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Read More on AXSM:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More